source
- Axiom Biosciences targets Hong Kong IPO to raise up to $200 million for regenerative therapy pipelineAxiom Biosciences, a San Diego‑based biotech, announced plans to list on the Hong Kong Stock Exchange rather than the traditional U.S. exchanges. The company aims to use the offering to secure new…
- Jupiter Neurosciences signs $100M deal for U.S. rights to PharmAla's MDMA therapy ALA-002Jupiter Neurosciences announced a licensing agreement with Canadian biotech PharmAla Biotech to obtain U.S. rights to an MDMA‑based drug, ALA‑002, aimed at treating neuropsychiatric conditions. Th…